title: An evidence-based review of a Lentinula edodes mushroom extract as complementary therapy in the surgical oncology patient.
abstract: The purpose of this review is to present the currently published evidence regarding the use, efficacy, potential mechanisms of action, and results of published clinical trials regarding the use of a Lentinula edodes mushroom-derived extract (active hexose correlated compound) as complementary therapy in patients with cancer. The authors explore the current preclinical and clinical evidence as it relates to this topic and its potential use in the surgical oncology patient. There has been a growing interest in stimulation of the immune system in trauma, cancer, and surgical patients in general. Little, however, has been written about some-of the supplements in widely used in Japan and China, but relatively unheard of in the United States.
authors.affiliation: Department of Pediatric Surgery, University of Texas Medical School at Houston, Houston, Texas 77030, USA.
authors.forename: Shinil K
authors.initials: SK
authors.lastname: Shah
authors.forename: Peter A
authors.initials: PA
authors.lastname: Walker
authors.forename: Stacey D
authors.initials: SD
authors.lastname: Moore-Olufemi
authors.forename: Alamelu
authors.initials: A
authors.lastname: Sundaresan
authors.forename: Anil D
authors.initials: AD
authors.lastname: Kulkarni
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Andrassy
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D000998:Antiviral Agents / Q000494:pharmacology; D001424:Bacterial Infections / Q000517:prevention & control; D001688:Biological Products / Q000494:pharmacology*; D002681:China; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D019317:Evidence-Based Medicine; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007564:Japan; D009369:Neoplasms / Q000188:drug therapy; D011134:Polysaccharides / Q000494:pharmacology*; D016032:Randomized Controlled Trials as Topic; D020942:Shiitake Mushrooms / Q000737:chemistry*; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D014481:United States; D014498:Uracil / Q000008:administration & dosage / Q000009:adverse effects; D014777:Virus Diseases / Q000517:prevention & control
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D001688:Biological Products; D011134:Polysaccharides; D003561:Cytarabine; D005641:Tegafur; D014498:Uracil; D003907:Dexamethasone; D002945:Cisplatin; C499366:Active Hexose Correlated Compound